the o2h SEIS fund - o2h Ventures

featured in

highlights
Invest in a portfolio of emerging university spin-outs and early-stage companies specializing in biotech therapeutics in the UK. We have made investments in several promising companies from the fund. These include Alevin Therapeutics, CardiaTec, Five Alarm Bio, and others.
Aiming to build a diverse portfolio with capital growth opportunities and various SEIS tax reliefs. The minimum investment amount for investors is £10k.
The biotech research sector is one of the leading sectors in the UK economy. The large pharma companies now rely on the small innovative biotech’s for new ideas in disease areas such as cancer and neurosciences, among others, which has led to higher potential exit valuations.
The team and the advisors operating o2h ventures have been active in grassroots science for over 20 years in the UK.


Sunil Shah, CEO - o2h Ventures

fund overview

Fund Status	Open
Fund Size	Target £10m
Current AUM	£ 1.1m
Manager AUM	£ 7.6m
Minimum Subscription	£ 10,000
Maximum Subscription	£ 2,00,000
Expected Exit	3-7 years
Founder's Investment	Minimum 10% of every investment
Income Tax Relief	Up to 50% of money invested*
Other Reliefs	Inheritance, Capital Gains, Loss and other reliefs

Contact Request Prospectus

SEIS tax relief is very attractive for UK tax payers

You invest £50k

SEIS gives you £25k tax relief from HMRC

IF COMPANY VALUE DOUBLES

Investment now worth £100k

£50k profit

+ £25k income tax relief

- £10k performance incentive

= £65k net profit

IF VALUE STAYS THE SAME

Investment still worth £50k

£0 profit

+ £25k income tax relief

- £0 performance incentive

= £25k net profit

IF COMPANY FAILS

Investment now worth £0

£50k loss

+ £25k income tax relief

+ £15,750 loss relief *

- £0 performance incentive

= £9,250 capital loss

* Loss relief calculated on higher rate tax bracket Worked example is net of any fund fees

*Tax relief depends on an individual’s circumstances and may change in the future.

why o2h ventures?

+History in grassroots science: We have a track record of nurturing and investing in emerging life science and tech companies – the o2h ventures team are leaders in the biotech community and have been involved as investors, holding various board/industry positions awe well as being engaged in grassroot scientific activity for over 20 years.

+Evaluation: Since its inception, the o2h group has developed a rigorous process to evaluate its deal flow, particularly regards seed investments. Opportunities come from a wide range of sources, as a result of the o2h group’s extensive network of contacts.

+Access to scientific talents: The team have developed access to some of the most interesting scientific ideas and talent in the UK, achieving a clearly differentiated position through its live working relationships, fostered over many years, working as a discovery services company. This potentially fives o2h ventures earlier access than competitor to some of the most promising companies.

+Business model: The business model identified by o2h ventures gives it an edge both in terms of access to opportunities as well as an understanding of the support they require post investment in terms of incubation. By combining access and incubation we are providing a unique opportunity, reducing investment risk by being deeply involved and the team believe that this will increase Fund’s prospects of making successful exits.

fund registered with